FDA rejects Capricor’s Duchenne cell therapy, raising regulatory risk for biotech
The FDA has rejected a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics, according to STAT. The decision follows a lengthy review process, with the agency declining to approve the treatment for use in patients.
This outcome signals persistent regulatory hurdles for companies developing advanced therapies in rare diseases. For biotech and pharma executives, the decision adds to uncertainty in planning and investment for novel treatments. Firms may need to reassess risk and timelines for similar products.